The clinical applications of FDG-PET in cancer detection

• Main Authors: Changlai, Sheng-Pin, 張賴昇平
• Other Authors: W-K Chen
• Format: Others
• Language: zh-TW
• Published: 2003
• Online Access: http://ndltd.ncl.edu.tw/handle/30569936063984142949

博士 === 中山醫學大學 === 醫學研究所 === 91 === The helpful of 18F-2-deoxyglucose positron emission tomography (FDG-PET) in restaging non-small cell lung cancer (NSCLC) has not been extensively evaluated. A total of 156 patients referred for restaging of NSCLC were retrospectively evaluated. According to the calssification of American Joint Committee on Cancer, stage I and stage II were definted as conventionally resectable, stage IIIA as locally advanced but resectable, stage IIIB as locally advanced but unresectable, and stage IV as absolutely unresectable. Compare to initial staging by chest computed tomographic findings, FDG-PET down-staged 45/156 (29%) and up-staged 52/156 (33%)NSCLCs. In addition, 37/156 (23%) patients were reclassified from resectable to unresectable and 22/156 (14%) patients were reclassified from unresectable to resectable. Our results prove the helpful thehelpfulness of whole body FDG-PET for restaging NSCLC.